Revenue
No reported data
ADIAL PHARMACEUTICALS, INC. (ADIL)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2021
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Research & development | $2.6M | $3.2M | $1.3M | $2.0M | $8.4M | $5.9M | $4.0M | $368,459 | $182,107 |
| Operating expenses | $7.8M | $8.3M | $6.9M | $10.9M | $19.3M | $10.9M | $8.2M | $7.0M | $995,286 |
| Operating income | −$7.8M | −$8.3M | −$6.9M | −$10.9M | −$19.3M | −$10.9M | −$8.2M | −$7.0M | −$995,286 |
| Net income | −$8.0M | −$13.2M | −$5.1M | −$12.7M | −$19.4M | −$10.9M | −$8.6M | −$11.6M | −$1.1M |
| Basic EPSper diluted share | -$11.93 | -$68.01 | -$3.60 | -$12.71 | -$1.04 | -$0.87 | -$0.87 | -$2.44 | -$0.35 |
| Diluted EPSper diluted share | -$11.93 | -$68.01 | -$3.60 | -$12.71 | -$1.04 | -$0.87 | -$0.87 | -$2.44 | -$0.35 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 12, 2026Form 4 | Young Wendy B.Director | BuyPre-funded Warrant · derivative | 36.4K | $2.75 | $100.0K | 36.4K |